Screener
Veracyte VCYT Testing revenue — Other cost
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:OtherCostOfOperatingRevenue.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Laboratory supplies and reagents expense | 12,314 | 13,067 |
| Sample collection expense | 3,288 | 2,825 |
| Compensation expense | 9,804 | 5,611 |
| Other cost of testing revenue (1) | 4,937 | 3,385 |
| Allocation of facilities and IT expenses | 2,963 | 3,372 |
| Total cost of testing revenue | 33,306 | 28,260 |
| Cost of product revenue: | ||
| Product costs | 1,401 | 109 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's testing revenue — other cost?
- Veracyte (VCYT) reported testing revenue — other cost of $4.94M in Q1 2026.
- How has Veracyte's testing revenue — other cost changed year-over-year?
- Veracyte's testing revenue — other cost increased by 45.8% year-over-year, from $3.39M to $4.94M.
- What is the long-term trend for Veracyte's testing revenue — other cost?
- Over 3 years (2022 to 2025), Veracyte's testing revenue — other cost has grown at a 25.6% compound annual growth rate (CAGR), from $9.91M to $19.65M.
- What does testing revenue — other cost mean?
- This encompasses miscellaneous direct costs associated with the testing segment that do not fall into primary categories like labor or reagents. It is used to track ancillary operational expenses that impact the gross margin of the testing business.
Ask your AI about Veracyte's testing revenue — other cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude